Peptides for post-cancer fertility

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Cancer treatments can severely compromise fertility, with up to 80% of young women and men experiencing some degree of reproductive dysfunction after chemotherapy or radiation, leading to significant emotional distress and impacting family planning [National Cancer Institute, 2024].. While fertility preservation strategies exist, peptides offer targeted approaches to both protect and potentially restore reproductive function post-cancer.

Cancer treatments can severely compromise fertility, with up to 80% of young women and men experiencing some degree of reproductive dysfunction after chemotherapy or radiation, leading to significant emotional distress and impacting family planning [National Cancer Institute, 2024]. While fertility preservation strategies exist, peptides offer targeted approaches to both protect and potentially restore reproductive function post-cancer.

GnRH Agonists: Protecting Ovarian Function During Treatment

Gonadotropin-releasing hormone (GnRH) agonists are a cornerstone of fertility preservation for premenopausal women undergoing chemotherapy. These peptides work by temporarily suppressing ovarian function, inducing a reversible, menopausal-like state. This quiescence is thought to protect ovarian follicles from the cytotoxic effects of chemotherapy, thereby reducing the likelihood of chemotherapy-induced ovarian insufficiency (CIOI) [Lee et al., 2021].

The 2018 ASCO guidelines recommend offering GnRH agonists to premenopausal women undergoing chemotherapy for breast cancer to reduce CIOI risk [Onclive, 2025]. Typical administration involves monthly subcutaneous or intramuscular injections, starting before chemotherapy and continuing throughout the treatment duration. While not a guarantee of fertility, studies suggest a significant reduction in ovarian damage. For instance, a meta-analysis by Lee et al. (2021) found that GnRH agonists significantly reduced the risk of CIOI in breast cancer patients. It's crucial to understand that GnRH agonists are a protective measure during treatment, not a restorative one after.

Kisspeptin: A Master Regulator for Fertility Restoration

Kisspeptin, a neuropeptide produced in the hypothalamus, is a master regulator of the hypothalamic-pituitary-gonadal (HPG) axis, which controls reproductive function. It stimulates the release of GnRH, which in turn triggers the secretion of gonadotropins (LH and FSH) from the pituitary, essential for ovulation and spermatogenesis. Exogenous administration of kisspeptin holds significant promise for restoring fertility in individuals with hypothalamic-pituitary dysfunction [Kotanidou et al., 2025].

Kisspeptin has been successfully used to stimulate ovulation in women undergoing in vitro fertilization (IVF) treatment and to improve the quality of human ovarian cryopreservation medium [Imperial BRC, 2020; Tavakoli et al., 2023]. While specific dosing for post-cancer fertility restoration is still under active research, typical clinical applications for IVF involve intravenous infusions or subcutaneous injections to precisely time ovulation. However, a critical nuance with kisspeptin is its complex relationship with cancer biology. Kisspeptin expression has been associated with metastasis and tumor growth in breast and ovarian cancer in some studies [Stathaki et al., 2019]. This oncological caveat necessitates extreme caution and thorough oncological clearance before considering kisspeptin for fertility restoration in cancer survivors, especially those with a history of hormone-sensitive cancers.

Follistatin: Modulating Reproductive Hormones

Follistatin is a glycoprotein that binds to and inhibits the activity of activins, which are members of the transforming growth factor-beta (TGF-β) superfamily involved in regulating various cellular processes, including reproduction. By inhibiting activins, follistatin can indirectly influence FSH secretion and ovarian function. In preclinical models, follistatin has shown potential in protecting ovarian reserve and improving reproductive outcomes [Wang et al., 2018]. However, its direct application for post-cancer fertility in humans is still largely experimental, and its oncological safety profile needs further elucidation.

Comparison: Protection vs. Restoration with Oncological Nuance

The distinction between GnRH agonists and kisspeptin for post-cancer fertility is crucial. GnRH agonists serve as a protective measure during chemotherapy, aiming to shield existing ovarian reserve from damage. Their mechanism is well-established, and their use is guided by clinical guidelines. Kisspeptin, conversely, is a potential restorative agent after treatment, aiming to re-activate or optimize the reproductive axis. While its efficacy in stimulating ovulation is promising, its theoretical oncological risks, particularly in hormone-sensitive cancers, present a significant hurdle. Therefore, the choice of peptide must be carefully considered based on the timing (during vs. after treatment) and the individual patient's oncological history, prioritizing established protective measures and rigorously evaluating any restorative therapies for safety.

Clinical Takeaway

For cancer survivors concerned about fertility, proactive planning is paramount. Premenopausal women undergoing chemotherapy should discuss GnRH agonists with their oncologist; monthly injections throughout treatment can significantly reduce the risk of chemotherapy-induced ovarian insufficiency. For fertility restoration post-treatment, kisspeptin shows promise in stimulating the reproductive axis, but its use requires extreme caution and thorough oncological clearance due to its potential association with tumor growth in certain cancers. Peptides like follistatin are still largely experimental. A comprehensive discussion with a reproductive endocrinologist and oncologist is essential to weigh the benefits and risks of any peptide intervention, ensuring that fertility goals are pursued without compromising oncological safety. Consider cryopreservation of gametes or embryos as primary fertility preservation strategies.

References